knowledge -WSS

knowledge

author：explore 2025-09-27 09:47:24 - browse：6

Pascal Soriot - Senate Finance Committee — AstraZeneca CEO Pascal Soriot Jacquelyn Martin/AP

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Last week, Medicare made its first offers to the makers of the 10 products subject to negotiation, though it said it would be up to the companies to discuss the proposals. On Thursday, at a press briefing at which they presented their 2023 earnings, AstraZeneca executives also played coy about the bargaining over the price of the company’s diabetes drug Farxiga.

“We have received the first offer, but as you can imagine, we will not disclose what the offer is,” Ruud Dobber, the company’s executive vice president of biopharmaceuticals business, said at the event, held at the London Stock Exchange. “We are in active negotiation, and it will be a few rounds of discussions” with Medicare.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： BMI, flaws aside, is found to be useful estimate of body fat in youth

WSS

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Senate panel puts off hardest PBM reforms for another day

Cord blood banking comes at a high cost to babies

Rise in cancer among younger people worries and puzzles doctors

Ultragenyx gene therapy for rare liver ailment succeeds in late

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Wikipedia

knowledge

entertainment

Guidelines to prevent youth baseball injuries need more muscle

Truvian presents data for its desktop blood

Continuity nursing helped my family in our darkest PICU moments

STAT Report: Patient voices and perspectives

Alkermes shareholders re

What it's like to live with paralysis for one psychologist

BioMarin wins approval for gene therapy to treat hemophilia A

Letters to First Opinion on caregivers, digital health, and more

Cancer drug shortages should be causing more outrage

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

hotspot

FDA's Pazdur wants cancer trials to range beyond China alone

Device maker Teleflex to acquire urology company for $600M

Let's speed up science by embracing open access publishing

With trial win, GSK could get blood cancer drug back on market

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Rise in cancer among younger people worries and puzzles doctors

focus

entertainment

entertainment

hotspot